Table 1.
Characteristics of persistent SARS-CoV-2 infected patients.
| Patient | Age Sex (M/F) | Primary disease | Immunosuppression | Co-morbidities | SARS-CoV-2 positivity duration (days) | Time to SARS-CoV-2 negativity (days) | Serum immuno-globulins | SARS-CoV-2 antibodies | Mortality (from last positive SARS-CoV-2 sample) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 71 M |
CLL | FCR chemotherapy (6 cycles, completed 6 m pre-COVID) |
Resp: NSIP/HP Other: hypo-gammaglobulinaemia post-chemotherapy |
305 | 310 | IgA + IgM low | Initially negative | 30-day: N 90-day: N 1-year: N |
| 2 | 53 F |
AML | Ongoing ciclosporin + Sorafenib Bone marrow transplant (6 months pre-COVID) |
Resp: ex-smoker Other: GvHD |
154 | Died while still positive | IgA + IgM low | Not tested | 30-day: Y 90-day: Y 1-year: Y |
| 3 | 58 F |
NHL | Obinutuzumab |
Resp: asthma, ex-smoker Other: nil |
269 | 296 | IgA + IgM low | Negative | 30-day: N 90-day: N 1-year: awaited |
| 4 | 80 F |
CLL | Previous Ibrutinib (stopped 1 m pre-COVID) |
Resp: ex-smoker Other: malignant melanoma, neutropaenia |
94 | Died while still positive | IgA low IgM normal |
Negative | 30-day: Y 90-day: Y 1-year: Y |
| 5 | 42 M |
ALL | Bone marrow transplant - haploidentical allograft (14 months pre-COVID) |
Resp: progressive pulmonary fibrosis Other: T2DM |
58 | 61 | IgA + IgM low | Not tested | 30-day: N 90-day: Y 1-year: Y |
| 6 | 69 F |
DLBCL | R-CHOP chemotherapy |
Resp: asthma Other: nil |
113 | 122 | IgA + IgM low | Not tested | 30-day: Y 90-day: Y 1-year: Y |
ALL - acute lymphoblastic leukaemia; AML - acute myeloid leukaemia; CLL - chronic lymphocytic leukaemia; DLBCL - diffuse large B-cell lymphoma; FCR - Fludarabine/cyclophosphamide/rituximab; GvHD - graft vs host disease; NHL - Non-Hodgkin lymphoma; NSIP/HP – non-specific interstitial pneumonitis/ hypersensitivity pneumonitis; T2DM - Type 2 diabetes mellitus.